WCN26-5285 C3 GLOMERULOPATHY ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY IN A PATIENT WITH MALIGNANT PLEURAL MESOTHELIOMA: A CASE REPORT

Read full text Summarise with VIRAT
Authors: Taiki Higashi, Ryosuke Yamamura, Daisuke Fujimoto, Tomoko Kanki, Terumasa Nakagawa, Yoshikazu Miyasato, Teruhiko Mizumoto, Yutaka Kakizoe, Masataka Adachi, Yuichiro Izumi, Takashige Kuwabara, Yukimasa Koda
+1 more Hideki Yokoi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the management of advanced malignancies but can provoke immune-related adverse events (irAEs). Renal irAEs most commonly manifest as acute tubulointerstitial nephritis; however, glomerular diseases are increasingly recognized. Several reports have indicated that glomerulonephritis induced by ICIs include C3 glomerulopathy (C3G), although its clinicopathological features under ICIs are not fully characterized. We report a biopsy-proven case of C3G during nivolumab plus ipilimumab therapy for malignant pleural mesothelioma, and describe its clinicopathological characteristics and diagnostic evaluation.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Cancer Immunotherapy and Biomarkers Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105687–105687
Publication date
25 March 2026
Language
EN